143 related articles for article (PubMed ID: 38826786)
21. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study.
Schjesvold FH; Dimopoulos MA; Delimpasi S; Robak P; Coriu D; Legiec W; Pour L; Špička I; Masszi T; Doronin V; Minarik J; Salogub G; Alekseeva Y; Lazzaro A; Maisnar V; Mikala G; Rosiñol L; Liberati AM; Symeonidis A; Moody V; Thuresson M; Byrne C; Harmenberg J; Bakker NA; Hájek R; Mateos MV; Richardson PG; Sonneveld P;
Lancet Haematol; 2022 Feb; 9(2):e98-e110. PubMed ID: 35032434
[TBL] [Abstract][Full Text] [Related]
22. Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study.
Kelly KR; Ailawadhi S; Siegel DS; Heffner LT; Somlo G; Jagannath S; Zimmerman TM; Munshi NC; Madan S; Chanan-Khan A; Lonial S; Chandwani S; Minasyan A; Ruehle M; Barmaki-Rad F; Abdolzade-Bavil A; Rharbaoui F; Herrmann-Keiner E; Haeder T; Wartenberg-Demand A; Anderson KC
Lancet Haematol; 2021 Nov; 8(11):e794-e807. PubMed ID: 34529955
[TBL] [Abstract][Full Text] [Related]
23. Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study.
Richardson PG; Bringhen S; Voorhees P; Plesner T; Mellqvist UH; Reeves B; Paba-Prada C; Zubair H; Byrne C; Chauhan D; Anderson K; Nordström E; Harmenberg J; Palumbo A; Sonneveld P
Lancet Haematol; 2020 May; 7(5):e395-e407. PubMed ID: 32213344
[TBL] [Abstract][Full Text] [Related]
24. Pomalidomide combined with dexamethasone for the treatment of relapsed/refractory multiple myeloma: a systematic review and meta-analysis.
Luo Y; Li C; Niu Y; Wu S; Tian J; Hu Z; He J; Zhang Z; Liu H; Li Y; Wang T; Fang Y
Expert Rev Hematol; 2024; 17(4-5):127-134. PubMed ID: 38421372
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of anti-CD38 monoclonal antibodies in patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials.
Ye L; Zhou F; Cheng D; Xie M; Yan X; Xue Y; Yang Q; Jia R; Zhong L; Yang L; Zou L; Huang N
Front Oncol; 2023; 13():1240318. PubMed ID: 38144527
[TBL] [Abstract][Full Text] [Related]
26. A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma.
Mikhael J; Richardson P; Usmani SZ; Raje N; Bensinger W; Karanes C; Campana F; Kanagavel D; Dubin F; Liu Q; Semiond D; Anderson K
Blood; 2019 Jul; 134(2):123-133. PubMed ID: 30862646
[TBL] [Abstract][Full Text] [Related]
27. Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.
Vogl DT; Dingli D; Cornell RF; Huff CA; Jagannath S; Bhutani D; Zonder J; Baz R; Nooka A; Richter J; Cole C; Vij R; Jakubowiak A; Abonour R; Schiller G; Parker TL; Costa LJ; Kaminetzky D; Hoffman JE; Yee AJ; Chari A; Siegel D; Fonseca R; Van Wier S; Ahmann G; Lopez I; Kauffman M; Shacham S; Saint-Martin JR; Picklesimer CD; Choe-Juliak C; Stewart AK
J Clin Oncol; 2018 Mar; 36(9):859-866. PubMed ID: 29381435
[TBL] [Abstract][Full Text] [Related]
28. Pomalidomide, dexamethasone, and daratumumab in Japanese patients with relapsed or refractory multiple myeloma after lenalidomide-based treatment.
Matsue K; Sunami K; Matsumoto M; Kuroda J; Sugiura I; Iwasaki H; Chung W; Kuwayama S; Nishio M; Lee K; Iida S
Int J Hematol; 2022 Jul; 116(1):122-130. PubMed ID: 35429329
[TBL] [Abstract][Full Text] [Related]
29. Optimal timing and drug combination of selinexor in multiple myeloma: a systematic review and meta-analysis.
Gu X; Sun C; Xu J; Lin Z; Zhang L; Zheng Y
Hematology; 2023 Dec; 28(1):2187972. PubMed ID: 36920065
[TBL] [Abstract][Full Text] [Related]
30. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.
Chari A; Vogl DT; Gavriatopoulou M; Nooka AK; Yee AJ; Huff CA; Moreau P; Dingli D; Cole C; Lonial S; Dimopoulos M; Stewart AK; Richter J; Vij R; Tuchman S; Raab MS; Weisel KC; Delforge M; Cornell RF; Kaminetzky D; Hoffman JE; Costa LJ; Parker TL; Levy M; Schreder M; Meuleman N; Frenzel L; Mohty M; Choquet S; Schiller G; Comenzo RL; Engelhardt M; Illmer T; Vlummens P; Doyen C; Facon T; Karlin L; Perrot A; Podar K; Kauffman MG; Shacham S; Li L; Tang S; Picklesimer C; Saint-Martin JR; Crochiere M; Chang H; Parekh S; Landesman Y; Shah J; Richardson PG; Jagannath S
N Engl J Med; 2019 Aug; 381(8):727-738. PubMed ID: 31433920
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma.
Dimopoulos MA; Palumbo A; Corradini P; Cavo M; Delforge M; Di Raimondo F; Weisel KC; Oriol A; Hansson M; Vacca A; Blanchard MJ; Goldschmidt H; Doyen C; Kaiser M; Petrini M; Anttila P; Cafro AM; Raymakers R; San-Miguel J; de Arriba F; Knop S; Röllig C; Ocio EM; Morgan G; Miller N; Simcock M; Peluso T; Herring J; Sternas L; Zaki MH; Moreau P
Blood; 2016 Jul; 128(4):497-503. PubMed ID: 27226434
[TBL] [Abstract][Full Text] [Related]
32. Cost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON Trial.
Dolph M; Tremblay G; Leong H
Pharmacoeconomics; 2021 Nov; 39(11):1309-1325. PubMed ID: 34368938
[TBL] [Abstract][Full Text] [Related]
33. Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis.
Bringhen S; Pour L; Vorobyev V; Vural F; Warzocha K; Benboubker L; Koh Y; Maisnar V; Karlin L; Pavic M; Campana F; Le Guennec S; Menas F; van de Velde H; Richardson PG
Leuk Res; 2021 May; 104():106576. PubMed ID: 33839618
[TBL] [Abstract][Full Text] [Related]
34. Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma.
Richardson PG; Oriol A; Larocca A; Bladé J; Cavo M; Rodriguez-Otero P; Leleu X; Nadeem O; Hiemenz JW; Hassoun H; Touzeau C; Alegre A; Paner A; Maisel C; Mazumder A; Raptis A; Moreb JS; Anderson KC; Laubach JP; Thuresson S; Thuresson M; Byrne C; Harmenberg J; Bakker NA; Mateos MV;
J Clin Oncol; 2021 Mar; 39(7):757-767. PubMed ID: 33296242
[TBL] [Abstract][Full Text] [Related]
35. Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma.
Fouquet G; Pegourie B; Macro M; Petillon MO; Karlin L; Caillot D; Roussel M; Arnulf B; Mathiot C; Marit G; Kolb B; Stoppa AM; Brechiniac S; Richez V; Rodon P; Banos A; Wetterwald M; Garderet L; Royer B; Hulin C; Benbouker L; Decaux O; Escoffre-Barbe M; Fermand JP; Attal M; Avet-Loiseau H; Moreau P; Facon T; Leleu X;
Ann Oncol; 2016 May; 27(5):902-7. PubMed ID: 26787238
[TBL] [Abstract][Full Text] [Related]
36. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK
Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475
[TBL] [Abstract][Full Text] [Related]
37. Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics.
Harrison SJ; Perrot A; Alegre A; Simpson D; Wang MC; Spencer A; Delimpasi S; Hulin C; Sunami K; Facon T; Vlummens P; Yong K; Campana F; Inchauspé M; Macé S; Risse ML; van de Velde H; Richardson P
Br J Haematol; 2021 Jul; 194(1):120-131. PubMed ID: 34036560
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of generic pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma: a multicenter, open-label, single-arm trial.
Zhou H; Wang Y; Chen J; He A; Jin J; Lu Q; Zhao Y; Li J; Hou M; Su L; Lai X; Wang W; Liu L; Ma Y; Gao D; Lai W; Zhou X; Jing H; Zhang J; Yang W; Ran X; Lin C; Hao J; Xiao T; Huang Z; Zhu Z; Wang Q; Fang B; Wang B; Song Y; Cai Z; Liu B; Zhu Y; Yang X; Kang X; Li J; Chen W
Ann Hematol; 2024 Mar; 103(3):855-868. PubMed ID: 38112795
[TBL] [Abstract][Full Text] [Related]
39. Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma.
Matsue K; Iwasaki H; Chou T; Tobinai K; Sunami K; Ogawa Y; Kurihara M; Midorikawa S; Zaki M; Doerr T; Iida S
Cancer Sci; 2015 Nov; 106(11):1561-7. PubMed ID: 26292221
[TBL] [Abstract][Full Text] [Related]
40. Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients.
Parisi MS; Leotta S; Romano A; Del Fabro V; Martino EA; Calafiore V; Giubbolini R; Markovic U; Leotta V; Di Giorgio MA; Tibullo D; Di Raimondo F; Conticello C
J Clin Med; 2019 Oct; 8(10):. PubMed ID: 31623097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
